Virios Therapeutics (Virios Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Virios Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Virios Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Virios Therapeutics's Cash-to-Debt or its related term are showing as below:

VIRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Virios Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was No Debt.

VIRI's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs VIRI: No Debt

Virios Therapeutics Cash-to-Debt Historical Data

The historical data trend for Virios Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Virios Therapeutics Cash-to-Debt Chart

Virios Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.09

No Debt

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Virios Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Virios Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virios Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's Cash-to-Debt falls into.

Virios Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Virios Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Virios Therapeutics had no debt ⁽¹⁾.

Virios Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Virios Therapeutics had no debt ⁽¹⁾.

Virios Therapeutics (NAS:VIRI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Virios Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009